Developing therapeutics for rare diseases often means working with small sample numbers. In this interview, Mark Dysinger, Developmental Scientist III, Bioanalytical Development, Alexion Pharmaceuticals, describes how miniaturized immunoassays enable accurate analysis of drug-target engagement. Hear how Gyros Protein Technologies’ Gyrolab® novel immunoassay technology overcomes the challenges of traditional ligand-binding assays used in the analysis of pharmacokinetics, pharmacodynamics and anti-drug antibodies, is suitable for regulated work, and how these assays can be easily transferred to partner laboratories.